Administer by subcutaneous injection. The first dose should be administered under the supervision of a healthcare professional. Patients may be trained to self-inject.

Adalimumab selectively binds to human TNFα, a naturally occurring cytokine involved in normal inflammatory and immune responses. It blocks the interaction of TNFα with its cell surface receptors (p55 and p75), thereby neutralizing the biological function of TNFα.

• •Active serious infections, including chronic or localized infections (e.g., sepsis, tuberculosis, opportunistic infections).
• •Moderate to severe heart failure (NYHA Class III/IV).
• •Hypersensitivity to adalimumab or any of the excipients.

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. Do not shake.

No dose-limiting toxicity was observed during clinical trials. In case of an overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment initiated.

Use during pregnancy only if clearly needed and after careful assessment of risks and benefits. Small amounts may be present in breast milk; consider developmental and health benefits of breastfeeding along with the mother’s clinical need for Advixa.